Adult prostatic sarcoma: A contemporary multicenter Rare Cancer Network study.

Détails

ID Serval
serval:BIB_1069B1CCABF4
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Adult prostatic sarcoma: A contemporary multicenter Rare Cancer Network study.
Périodique
The Prostate
Auteur(s)
De Bari B., Stish B., Ball M.W., Habboush Y., Sargos P., Krengli M., Bossi A., Stabile A., Sole Pesutic C., Lestrade L., Smeenk R.J., Jereczek-Fossa B.A., Zilli T., Créhange G., Alongi F., Zaorsky N., Ozsahin M.
ISSN
1097-0045 (Electronic)
ISSN-L
0270-4137
Statut éditorial
Publié
Date de publication
07/2017
Peer-reviewed
Oui
Volume
77
Numéro
10
Pages
1160-1166
Langue
anglais
Notes
Publication types: Journal Article ; Multicenter Study
Publication Status: ppublish
Résumé
Adult prostatic sarcoma (PS) is a rare disease. While surgery is considered the standard approach, the role of other therapies is not completely established. We report results of the largest multicentric contemporary cohort of PS patients.
This study included 61 adult PS patients treated in 16 American and European Institutions. Median age was 64.4 years (range: 22-87). Curative surgery was delivered in 48 patients (prostatectomy = 26, cystoprostatectomy = 22), usually with lymphadenectomy (n = 40). Curative radiotherapy (RT) was delivered in 32 patients, as radical (n = 5), neoadjuvant (n = 10), or postoperative treatment (n = 17). Eighteen patients received chemotherapy. None of the patients received hormonal therapy.
Median follow-up was 72 months (95%CI: 55-not reached). Five-year local control (LC), overall survival (OS), cancer-specific survival, disease-free survival, and metastases-free rates were 47%, 53%, 56%, 35%, and 35%, respectively. Notably, curative RT (neoadjuvant, adjuvant, or definitive) was associated with improved 5-year LC (55% vs. 31%, P = 0.02) and OS (59% vs. 46%, P = 0.1). Surgically treated patients presenting with a cT3-4 tumor (n = 31), who received RT (n = 24), had a significantly improved 5-year LC (68% vs, 33%, P = 0.004) and OS (65% vs. 21%, P < 0.001) rates compared to patients not receiving RT. cT4 patients demonstrated a significantly lower 5-year OS (43% vs. 61%, P = 0.006) and LC (29% vs. 69%, P < 0.001) rates. Histologic subtype was not associated with LC and OS, but patients with prostatic stromal sarcoma, rhabdomyosarcoma, or sarcomatoid carcinoma had worse 5-year LC compared to other types (47% vs. 55%) and OS (49% vs. 58%).
Adult PS has a poor prognosis. Locally advanced tumors have poor LC and OS rates. Curative RT should be considered part of the multidisciplinary approach to PS.

Mots-clé
Adult, Aged, Antineoplastic Agents/therapeutic use, Combined Modality Therapy/methods, Combined Modality Therapy/statistics & numerical data, Humans, International Cooperation, Lymph Node Excision/methods, Lymph Node Excision/statistics & numerical data, Male, Middle Aged, Neoplasm Grading, Neoplasm Staging, Prognosis, Prostate/pathology, Prostatectomy/methods, Prostatectomy/statistics & numerical data, Prostatic Neoplasms/mortality, Prostatic Neoplasms/pathology, Prostatic Neoplasms/therapy, Radiotherapy/methods, Radiotherapy/statistics & numerical data, Rare Diseases/mortality, Rare Diseases/pathology, Rare Diseases/therapy, Sarcoma/mortality, Sarcoma/pathology, Sarcoma/therapy, Survival Analysis, chemotherapy, multimodal treatment, prognostic factors, prostatic sarcoma, radiotherapy, surgery
Pubmed
Web of science
Création de la notice
22/06/2017 19:09
Dernière modification de la notice
20/08/2019 12:37
Données d'usage